指南与共识重症综合管理与镇静镇痛呼吸衰竭与机械通气

接受前稀释与后稀释联合CVVH的重症肺炎患者万古霉素药代动力学及维持剂量推荐

Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution.
指南 / 共识 · Eur J Clin Pharmacol · 2019-11-16
一句话结论接受前稀释与后稀释联合CVVH的重症肺炎患者,万古霉素维持剂量推荐为每12小时400-650 mg,以达到稳态谷浓度15-20 mg/L,需密切监测血药谷浓度。

该前瞻性研究在大学医院ICU纳入10例接受万古霉素与CVVH治疗的重症肺炎患者,测定初始与稳态药代动力学。CVVH采用前稀释与后稀释混合模式,血流速180 mL/min,超滤液流速30-40 mL/kg/h。初始给药后平均筛系数为0.72±0.02,CVVH清除率(1.35±0.03 L/h)占总清除率(2.36±0.72 L/h)的60.55%±13.69%;稳态时筛系数为0.71±0.03,CVVH清除率(1.34±0.06 L/h)占总清除率(2.03±0.27 L/h)的66.96%±6.05%。基于总清除率计算的维持剂量为每12小时400-650 mg,以达到稳态谷浓度15-20 mg/L。作者认为单次或多次给药不影响筛系数和CVVH清除率,由于治疗水平难以维持,需密切监测血清谷浓度。

要点

  • 接受前稀释与后稀释联合CVVH的重症肺炎患者,万古霉素维持剂量推荐为每12小时400-650 mg,以达到稳态谷浓度15-20 mg/L。
  • CVVH参数为血流速180 mL/min、超滤液流速30-40 mL/kg/h、前稀释与后稀释混合模式。
  • 初始给药后CVVH清除率1.35±0.03 L/h,占总清除率2.36±0.72 L/h的60.55%±13.69%。
  • 稳态时CVVH清除率1.34±0.06 L/h,占总清除率2.03±0.27 L/h的66.96%±6.05%。
  • 单次给药与多次给药不影响筛系数和CVVH清除率,但治疗水平难以维持,需密切监测血清谷浓度。

适用人群与场景

  • 重症肺炎并接受静脉万古霉素治疗同时行CVVH的ICU患者。

诊断标准与关键阈值

  • 目标稳态谷浓度为15-20 mg/L。

处置流程与药物剂量

  • CVVH采用前稀释与后稀释混合模式,血流速180 mL/min,超滤液流速30-40 mL/kg/h。
  • A组仅接受初始剂量500 mg;B组接受500 mg每12小时直至达到稳态。
  • 基于总清除率计算的万古霉素维持剂量为每12小时400-650 mg,以达到稳态谷浓度15-20 mg/L。
  • 需密切监测血清万古霉素谷浓度。

研究设计与关键结果

  • 前瞻性研究,纳入10例重症肺炎接受万古霉素与CVVH治疗的患者,测定初始与稳态药代动力学。
  • 初始给药后平均筛系数0.72±0.02,CVVH清除率1.35±0.03 L/h,占总清除率2.36±0.72 L/h的60.55%±13.69%。
  • 稳态时筛系数0.71±0.03,CVVH清除率1.34±0.06 L/h,占总清除率2.03±0.27 L/h的66.96%±6.05%。
  • 基于总清除率计算的维持剂量为每12小时400-650 mg,以达到稳态谷浓度15-20 mg/L。
  • 单次给药或多次给药不影响筛系数和CVVH清除率。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,由于接受CVVH的重症肺炎患者治疗性万古霉素水平难以维持,需密切监测血清谷浓度。
  • 对于接受前稀释与后稀释联合CVVH的重症肺炎患者,可参考每12小时400-650 mg的维持剂量以达到稳态谷浓度15-20 mg/L。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Therapeutic vancomycin levels are difficult to maintain in severe pneumonia patients who are receiving IV vancomycin therapy while on continuous venovenous hemofiltration (CVVH). The objective of this study was to determine the pharmacokinetics and maintenance dose recommendations of vancomycin in severe pneumonia patients receiving CVVH.

METHODS: A prospective study was conducted in the intensive care unit of a university hospital. Ten severe pneumonia patients receiving vancomycin and CVVH treatment were determined the initial and steady-state pharmacokinetics of vancomycin. CVVH was performed in mixed predilution and postdilution mode with a blood flow rate of 180 mL/min and an ultrafiltrate flow rate of 30-40 mL/kg/h. Group A received an initial dose of 500 mg only, whereas group B received 500 mg every 12 h until steady state is achieved. Serum and ultrafiltrate were collected over 12 h after infusion of vancomycin.

RESULTS: After initial dosing, the mean sieving coefficient (SC) was 0.72 ± 0.02, and CVVH clearance (CLCVVH, 1.35 ± 0.03 L/h) constituted 60.55% ± 13.69% of total vancomycin clearance (CLtot, 2.36 ± 0.72 L/h). When steady state was reached, the SC of the patients was 0.71 ± 0.03, and the CLCVVH (1.34 ± 0.06 L/h) accounted for 66.96% ± 6.05% of the CLtot (2.03 ± 0.27 L/h). The recommended maintenance dose for vancomycin in severe pneumonia patients was 400-650 mg every 12 h, which was calculated based on CLtot, to achieve a trough concentration of 15-20 mg/L at steady state.

CONCLUSIONS: Single administration or multiple administration does not affect SC and CLCVVH. Owing to therapeutic vancomycin levels is difficult to maintain in severe pneumonia patients who are receiving IV vancomycin therapy while on CVVH, close monitoring of serum trough concentrations is required.

来源:Eur J Clin Pharmacol,查看原文。版权归原作者所有。

参考来源

  1. Li Q, Liang F, Sang L, et al. Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution. Eur J Clin Pharmacol. 2019. PMID: 31734748. doi:10.1007/s00228-019-02755-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。